We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
+13.7%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$339M
AUM Growth
+$7.5M
Cap. Flow
-$18.1M
Cap. Flow %
-5.36%
Top 10 Hldgs %
55.99%
Holding
39
New
12
Increased
4
Reduced
11
Closed
12

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$26.9M
2
A icon
Agilent Technologies
A
+$16.5M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
LLY icon
Eli Lilly
LLY
+$15.6M
5
SWTX
SpringWorks Therapeutics
SWTX
+$14.1M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.5M
2
MRK icon
Merck
MRK
+$21.7M
3
AMGN icon
Amgen
AMGN
+$20.1M
4
BIIB icon
Biogen
BIIB
+$17.8M
5
KVUE icon
Kenvue
KVUE
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$165B
$30.1M 8.88%
359,025
+66,066
+23% +$5.04M
BMY icon
2
Bristol-Myers Squibb
BMY
$123B
$29.7M 8.77%
+574,057
New +$26.9M
RPRX icon
3
Royalty Pharma
RPRX
$25.4B
$18.8M 5.55%
664,859
-27,441
-4% -$760K
A icon
4
Agilent Technologies
A
$36.8B
$17.9M 5.28%
+120,485
New +$16.5M
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.81B
$15.9M 4.7%
286,803
-78,197
-21% -$3.98M
LEGN icon
6
Legend Biotech
LEGN
$4.49B
$15.9M 4.69%
325,953
-17,177
-5% -$915K
INSM icon
7
Insmed
INSM
$23.2B
$15.8M 4.65%
215,884
-11,753
-5% -$867K
LLY icon
8
Eli Lilly
LLY
$1.02T
$15.3M 4.52%
+17,299
New +$15.6M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$70.5B
$15.2M 4.49%
+14,476
New +$16.1M
HRMY icon
10
Harmony Biosciences
HRMY
$1.94B
$15.1M 4.44%
376,315
+80,544
+27% +$2.83M
PRGO icon
11
Perrigo
PRGO
$1.47B
$14.6M 4.32%
557,937
+457,937
+458% +$12.6M
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$15.3B
$13.1M 3.86%
+117,500
New +$12.9M
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
$12.1M 3.58%
+378,453
New +$14.1M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.05B
$11.8M 3.48%
+518,677
New +$8.48M
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.78B
$10.5M 3.09%
83,756
-5,623
-6% -$777K
BBIO icon
16
BridgeBio Pharma
BBIO
$15.8B
$10.1M 2.98%
396,388
+84,688
+27% +$2.22M
AXSM icon
17
Axsome Therapeutics
AXSM
$11.4B
$9.51M 2.81%
+105,767
New +$9.23M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.38B
$8.29M 2.45%
+186,623
New +$8.48M
IOVA icon
19
Iovance Biotherapeutics
IOVA
$2.24B
$8.23M 2.43%
+876,009
New +$8.3M
NTLA icon
20
Intellia Therapeutics
NTLA
$1.53B
$8.03M 2.37%
+390,622
New +$9.01M
VERA icon
21
Vera Therapeutics
VERA
$2.66B
$7.64M 2.26%
172,876
-57,124
-25% -$2.17M
ACLX
22
DELISTED
Arcellx
ACLX
$7.5M 2.22%
89,863
-97,137
-52% -$6.47M
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$7.39M 2.18%
+160,947
New +$6.98M
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$2.32B
$6.07M 1.79%
798,137
-1,177,161
-60% -$8.95M
ELVN icon
25
Enliven Therapeutics
ELVN
$3.69B
$5.31M 1.57%
207,896
-15,089
-7% -$349K
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Cutter Capital Management held 39 positions worth $339M, up 2.3% from $331M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Cutter Capital Management withdrew a net $18.1M in Q3 2024, closing 12 positions and reducing 11 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier, followed by Consumer Staples.

Against the trend, Cutter Capital Management opened a new position in Bristol-Myers Squibb worth $29.7M.

  • Cutter Capital Management's largest Q3 2024 buy was Bristol-Myers Squibb: 574,057 shares worth $29.7M.
  • Cutter Capital Management added most to Perrigo in Q3 2024, an estimated $12.6M increase.
  • Cutter Capital Management's biggest Q3 2024 reduction was BioCryst Pharmaceuticals, cutting an estimated $8.95M.
  • Cutter Capital Management fully exited BioMarin Pharmaceuticals in Q3 2024, selling an estimated $22.5M.
  • Cutter Capital Management's ten largest holdings make up 56% of its $339M portfolio in Q3 2024.
  • Cutter Capital Management opened 12 new positions and closed 12 in Q3 2024.
  • Cutter Capital Management's portfolio value rose 2.3% quarter-over-quarter to $339M.

Based on Cutter Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.